- 1 **Title:** Changing patterns of cigarette and ENDS transitions in the USA: a multistate transition analysis of
- 2 adults in the PATH Study in 2017–2019 vs 2019–2021
- 3 **Authors:** Andrew F. Brouwer^{1,*}, Jihyoun Jeon¹, Evelyn Jimenez-Mendoza¹, Stephanie R. Land², Theodore
- 4 R. Holford³, Abigail S. Friedman⁴, Jamie Tam⁴, Ritesh Mistry⁵, David T. Levy⁶, Rafael Meza⁷

5 Affiliations:

- 6 1. Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States
- 7 2. Tobacco Control Research Branch, National Cancer Institute, Rockville, MD, United States
- 8 3. Department of Biostatistics, Yale University, New Haven, CT, United States
- 9 4. Department of Health Management and Policy, Yale University, New Haven, CT, United States
- 10 5. Department of Health Behavior and Health Education, University of Michigan, Ann Arbor, MI,
- 11 United States
- 12 6. Department of Oncology, Georgetown University, Washington, DC, United States
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia,
 Canada
- 15 **Corresponding authors**^{*}: email: brouweaf@umich.edu; mail: Department of Epidemiology, 1415
- 16 Washington Heights, Ann Arbor, MI, 48109, United States
- 17 Word count:
- 18

19 Abstract 20 Introduction: The use of cigarettes and electronic nicotine delivery system (ENDS) has likely changed 21 since 2019 with the rise of pods and disposables, the outbreak of lung injuries related to vaping THC, 22 flavor bans, and the COVID pandemic. We analyzed patterns of initiation, cessation, and transitions 23 between cigarettes, ENDS, and dual use before and after 2019. 24 Methods: Using the Population Assessment of Tobacco and Health (PATH) Study, we applied a 25 multistate transition model to 28,061 adults in Waves 4-5 (2017-19) and 24,751 adults in Waves 5-6 26 (2019–21), estimating transition rates for initiation, cessation, and switching products for each period 27 overall and by age group. 28 **Results:** Cigarette initiation among adults who never used either product decreased from 2017–19 to 29 2019-21, but ENDS initiation did not significantly change. Persistence of ENDS-only use remained 30 high, with 75-80% still using ENDS only after 1 year. Cigarette-only use transitions remained similar, 31 with about 88% remaining, 7% transitioning to non-current use, and 5% transitioning to dual or ENDS-32 only use. In contrast, dual use to ENDS-only transitions increased from 9.5% (95%CI: 7.3-11.7%) to

- 20.1% (95%CI: 17.5–22.7%) per year from 2017–19 to 2019–21, decreasing the persistence of dual use. The dual use to cigarette-only transition remained at about 25%. These changes were qualitatively similar across adult age groups, though adults ages 18–24 years exhibited the highest probability of switching from cigarette-only use to dual use and from dual use to ENDS-only use.
- 37 Conclusions: Persistence of ENDS use among adults remained high in 2019–21, but a larger fraction of
 38 dual users transitioned to ENDS-only use compared to 2017–19. Because the fraction of cigarette 39 only users switching to dual use remained low, the public health implications of the increased dual
 40 use to ENDS-only transition are minimal.
- 41 **Keywords:** tobacco, cigarette, electronic nicotine delivery system (ENDS), dual use, transition, 42 multistate transition model

44 Introduction

45 The landscape of tobacco and nicotine products in the US and other countries has evolved quickly over 46 the past decade. Electronic nicotine delivery systems (ENDS), including e-cigarettes, have transformed 47 from cig-a-likes, refillables, and tank systems—which initially used freebase nicotine that was 48 unpalatable at higher nicotine concentrations—to pod mods and disposables that use nicotine salts, often perceived as less harsh.¹⁻⁵ As ENDS products have changed, so too have patterns of transitions 49 between ENDS and cigarette products.^{6,7} Moreover, recent events and policies, including the lung injury 50 outbreak in 2019,⁸ the COVID-19 pandemic, and the increasing restriction of ENDS flavors,⁹ may have 51 further shifted patterns of use and transition between ENDS and cigarettes. 52

Understanding product transitions is key to determining the likely public health benefit or harm of 53 ENDS.¹⁰⁻¹² If ENDS promote cigarette cessation, reduced smoking, or divert those who would have 54 otherwise smoked, there would be a benefit to public health.¹³⁻¹⁶ However, there remain concerns 55 about youth initiation, particularly as many flavors are targeted to youth,^{17,18} as well as concerns that 56 57 ENDS may interfere with long-term cigarette cessation because of continued or enhanced nicotine addiction.¹⁹⁻²¹ Many of the clinical trials that suggested ENDS can facilitate cigarette cessation used early 58 generation products that bear little resemblance to products more recently on the market,^{13,14} and the 59 60 real-world effectiveness may differ from the efficacy measured in clinical trials for many reasons. Hence, 61 continued analysis of how actual transition rates change over time is important for tracking real-world 62 associations between ENDS and other product use and providing the information necessary to project future public health outcomes. 63

In previous work, we analyzed transitions in the Population Assessment of Tobacco and Health (PATH) Study Waves 1–5 (2013–19), a nationally representative longitudinal survey of the US, using a multistate transition model.^{6,7} Multistate transition models estimate the transition rates that underly observed transitions between product.^{22–31} In this analysis, we extend our models to compare transitions observed in PATH in 2017–19 to 2019–21.

69 Methods

70 Data

The Population Assessment of Tobacco and Health (PATH) Study is a nationally representative longitudinal cohort study of tobacco and nicotine product use behaviors in the US among the civilian,

noninstitutionalized adult population. Our analysis compared 28,061 adults in the Wave 4 cohort in
Waves 4–5 (Dec 2016 to Nov 2019, abbreviated as 2017–19) and 24,751 adults in the Wave 4 cohort in
Waves 5–6 (Dec 2018 to Nov 2021, abbreviated as 2019–21). Although this analysis primarily focuses on
the differences between 2017–19 and 2019–21, we include previous results in 2015–17 in the
supplementary material for comparison purposes (Figures S1–S3).⁷

Follow-up time for participants was approximately two years between Waves 4 and 5 and between Waves 5 and 6, and follow-up time was treated as exactly two years in the model. The multistate transition framework explicitly accounts for the time between observations and for potential unobserved transitions, so one-year transition probabilities can be estimated from two-year data. We categorized participants as ages 18–24, 25–34, or 35–90 years. This set of groups was chosen because our transition estimates were not well-powered for participants ages 55–90 alone in 2019–21.

84 Each participant's product use was categorized as never established use (of either product), non-current use, cigarette-only use, ENDS-only use, or dual use of cigarettes and ENDS, as in previous work.^{6,7} 85 86 Established cigarette use was defined as having smoked at least 100 cigarettes in one's lifetime, and 87 established ENDS use was defined as ever "fairly regularly" using ENDS. Current use of cigarettes and 88 ENDS was defined as any past 30-day use by an established use of that product, and current dual use 89 was defined as current use of both cigarettes and ENDS by established users of both products. Non-90 current use was defined as no past 30-day use of either product by a participant who had established 91 use of one or both products. Characteristics of the populations are given in the supplementary material 92 (Table S1). This analysis was not regulated as human subjects research (University of Michigan 93 Institutional Review Board HUM00162265).

94 Transition modeling

95 We applied our multistate transition model to analyze the underlying transition hazard rates between 96 product use for adults overall and in each of the three age categories (18–24, 25–34, or 35–90 years) in 97 each of the two time periods (2017–19, 2019–21). Multistate transition models are finite-state, 98 stochastic process models that assume that transition hazard rates depend only on the current state and 99 not on past states or transition history. Technical details of the multistate transition model are provided 100 in the Supplemental Material. Using discrete-time observations, the model estimated instantaneous risk 101 of transition from one state to another, i.e., transition hazard rates, which collectively define the 102 probability of transitioning from one state to any other at a future time. We incorporated Wave 4

longitudinal survey weights into the model. Using the estimated transition rates, we estimated the 1year transition probabilities for each group for the two time periods separately. Additionally, two-sided p-values for whether transition rates were significantly different between periods were calculated as described in the Supplemental Material using the replicate weights provided by PATH. Multistate transition models were estimated using the wmsm function⁶ in R (publicly available at <u>https://tcors.umich.edu/Resources Research.php</u>), which is an extension of the msm function³² modified to incorporate participant weights.

110 **Results**

- 111 Over 2019–21, the average weighted prevalence of never established use was 57.7%, the prevalence of
- non-current use was 23.7%, the prevalence of cigarette-only use was 14.2%, the prevalence of ENDS-
- only use was 2.5%, and the prevalence of dual cigarette and ENDS use was 1.9%.

114 Transition hazard rates

- 115 There were three transitions that statistically significantly changed between 2017–19 and 2019–21
- 116 (Figure 1). The transition rate of cigarette initiation declined for adults in 2019–21 (p=0.02). The
- transition rate from ENDS-only use to non-current use increased in 2019–21 (p=0.005). The dual use to
- 118 ENDS-only use transition also increased in 2019–21 rate (p<0.001).
- Figure 1: Transition hazard rates among adults in 2017–19 (Waves 4–5) and 2019–21 (Waves 5–6). A
 version of this figure including previous results from 2015–17 (Waves 2–4) is given in Figure S1.

121 Transition probabilities

122 The changing transition rates resulted in changes in the 1-year transition probabilities (Figure 2). The 123 transition patterns for those with never established use, non-current use, and cigarette only use remained largely similar between the two periods, with the large majority remaining in the same use 124 125 state (never established use persistence: 98.8% (95% CI: 98.6–98.9%) and 98.6% (95% CI: 98.4–98.8%) in 126 the two periods; non-current use persistence: 96.3% (95%CI: 95.9-96.7%) and 96.8% (95%CI: 96.4-97.2%); and cigarette-only use: 88.2% (95%CI: 87.3-89.9%) and 88.2% (95%CI: 87.4-89.0%)). ENDS 127 128 uptake among adults who only use cigarettes remained low, with 3.8% (95%CI: 3.4-4.2%) and 4.0% 129 (95%Cl: 3.5–4.4%) transitioning.

The ENDS cessation probability increased slightly from 13.9% (95%CI: 11.9–16.0%) to 18.1% (95%CI:
16.2–19.9%). The transition patterns for those who dual used both products changed substantially over

this period, driven by the increase in cigarette cessation. Specifically, from 2017–19 to 2019–21, the transition probability from dual to cigarette-only use did not significantly change, but the transition probability from dual to ENDS-only use nearly doubled, increasing from 9.5% (95%CI: 7.3–11.7%) to 20.1% (95%CI: 17.5–22.7%). This increase was at the expense of the persistence of dual use, which decreased from 63.8% (95%CI: 59.9–67.6%) to 50.0% (95%CI: 46.1–54.0%) between the periods. There was no analogous increase in the cigarette-only to non-current use transition, which remained low at 6.8% (95%CI 6.2–7.5%) and 7.1% (6.4–7.7%) in the two periods.

- 139 **Figure 2**: One-year transition probabilities for adults in A. 2017–19 (Waves 4–5), and B. 2019–21 (Waves
- 140 5–6). Confidence intervals, including previous results from 2015–17 (Waves 2–4), are shown in Figure S2.
- 141 The transitions weighted by each use state's prevalence are given in Figure S4.

Considering the age-stratified transition probabilities (Figure 3), most of the changes in transitions for those using ENDS only or dual using both products were qualitatively similar across the age groups. The persistence of e-cigarette-only use remained similar in 2017–19 and 2019–21, decreasing somewhat for ages 25–34 only. Persistence of dual use decreased in 2019–21 for all three groups, accompanied by an increase in the transition probability of dual to ENDS-only.

- In 2019–21, young adults ages 18-24 were more likely to transition from cigarette-only use to dual use
 15.3% (95%CI: 9.6–21.0%) than those ages 25–34 (6.8% (95%CI: 5.4–8.2%)) or ages 35–90 (2.3% (95%CI:
 1.9–2.7%)). Additionally, while the dual use to ENDS-only transition increased for all age groups, it was
 higher for young adults (28.0% (95%CI: 21.6–34.4%) than for the other two ages groups (19.2% (95%CI:
 14.2–24.1%) and 16.8% (95%CI: 13.0–20.7%), respectively).
- 152
- Figure 3: One-year transition probabilities for adults ages 18–24 (A–C), ages 25–34 (D–F), and ages 35– 90 (G–I). Each of the three plots compares periods 2015–17 (Waves 2–4), 2017–19 (Waves 4–5), and 2019–21 (Waves 5–6). Confidence intervals, including previous results from 2015–17 (Waves 2–4), are shown in Figure S3.

157

158 **Discussion**

159 Changing marketplaces, policy environments, public health crises, and evolving attitudes and 160 perceptions of products have made it difficult to predict short-term patterns of use of cigarettes and

161 ENDS, let alone their longer-term impacts on public health. In previous work, we had identified dramatic 162 increases in the persistence of ENDS-only and dual use of cigarettes and ENDS around the time of the marketplace shift to pod mod products, including JUUL.⁷ Here, we found that many of the transition 163 164 rates that significantly changed from 2015–17 to 2017–19 did not significantly change again in 2017–19 165 to 2019–21 (Figure S1), including the non-current to cigarette-only use, cigarette-only to non-current 166 use, ENDS-only to dual use, and dual to cigarette-only use transitions. We did find three significant 167 changes in transition rates from 2017–19 to 2019–21: a decline in never-established to cigarette-only 168 use, an increase in ENDS-only to non-current use, and an increase in dual to ENDS-only use. From the 169 perspective of reducing cigarette use, these changes appear to be beneficial, but the big picture 170 underscores the overall public health challenge (Figure S4), with high persistence of cigarette, ENDS, and 171 dual use. In particular, because dual use remained uncommon (1.9% among adults overall) and ENDS 172 uptake among adults who smoke cigarettes remained low (<5% switching to dual or ENDS-only use in 173 one year), particularly for those ages 25 and older, the population public health impact of the increase in 174 the dual to ENDS-only use transition is likely to be limited.

175 While dual use remained persistent, potentially fueling concerns that continued nicotine addiction 176 through ENDS use may make cigarette cessation more difficult, there is evidence of increased harm 177 reduction as well, with an increased fraction of adults who dual used both products having transitioned 178 to ENDS-only use. Although that fraction remains small (overall, we estimated 20.1% of those who used 179 both products transitioned to ENDS-only use in one year), it exceeded the fraction of participants who 180 transitioned from cigarette-only to non-current use (7.1% overall). However, we cannot attribute the 181 increased cigarette cessation from dual use to participants' use of ENDS; the pattern may be a result of 182 demographic differences between dual and cigarette users or of ENDS use being an indicator of trying to 183 quit. Additionally, our results continue to highlight the importance of understanding the different 184 patterns among different stages of adulthood. Adoption of ENDS among those who currently or 185 previously used cigarettes was much greater among those ages 18–24 (15.3%) than among those ages 186 25-34 (6.8%) and was nearly negligible among older adults (2.3%) in 2019-21.

There were multiple major public health events and policy changes during the 2019–21 period that could have affected public perception and behaviors around cigarette and ENDS use. Following sharply increased rates of ENDS use among youth in 2018, , the US Surgeon General declared youth ENDS use to be an "epidemic"³³ Less than a year later, the outbreak of vaping-related lung injuries began in August

2019 and continued through the end of the year.⁸ Although the injuries are now thought to largely be associated with the use of vitamin E acetate as a diluent for tetrahydrocannabinol (THC) containing liquids, early CDC reports suggested nicotine vaping as the cause.^{8,34} The consequent emphasis on dangers of vaping in US news resulted in more negative public perceptions of ENDS use and more of the public discourse focusing on their potential dangers to youth,^{35–39} in contrast to countries like the UK, where there has been more emphasis on ENDS' potential benefits for adults.^{40,41} Additionally, in the US, many states and localities enacted restrictions or bans on flavored ENDS sales in 2020 and 2021.⁹

Early 2020 marked the start of the COVID-19 pandemic in the US, as SARS-CoV-2 spread rapidly across the country. Cigarette smoking was quickly found to be a risk factor for severe COVID-19 outcomes,^{42–44} and many studies linked greater perceived risk from COVID-19 to increased motivation to quit smoking.^{45–47} At the same time, elevated stress, particularly during lockdown or similarly restrictive periods, may have led to increased nicotine use as a coping mechanism.⁴⁸ Ultimately, COVID-19 appears to have resulted in a combination of conflicting pressures for and against tobacco and nicotine product use.⁴⁹

205 Given the period's many public health events and policy changes, it is perhaps surprising that we do not 206 see more changes in transition patterns for adults who use cigarettes only or ENDS only between 2017-207 19 and 2019–21. We did find a small increase in the ENDS-only to non-current use rate, but we found no 208 change in the initiation rate of ENDS among never established users of cigarettes or ENDS nor in the 209 ENDS cessation rate among those using both cigarettes and ENDS. Because the 2019 PATH data 210 collection period encompassed December 2018 to November 2019, the changes we previously found 211 between 2015–17 and 2017–19 may already reflect some of the changes discussed above. Also, because 212 of the local nature of flavor restrictions, the impacts of those restrictions may not be observed at the 213 national scale. Further, any changes in perceptions and behavior may have been short-lived, e.g., if lunginjury-related hesitance to use ENDS in 2019 or COVID-related motivation to quit smoking in early 2020 214 215 became irrelevant by the time PATH collected data in 2021. Or, the lack of change may represent the 216 disruption of existing trends, e.g., if more adults who smoke cigarettes would have taken up ENDS in the 217 absence of the lung injury outbreak and flavor restrictions. Because we cannot know what would have 218 happened without these events, we cannot be certain about the extent to which any individual public 219 health event or policy change was associated with the observed transition changes.

220 The strengths of our analysis include the high-quality, nationally representative data collected by PATH 221 and our multistate transition analysis allowing us to analyze the population-level changes in the 222 transition rates that underly observed changes in transition probabilities over time. Additionally, our 223 results continue to highlight the importance of understanding the different patterns of nicotine product 224 use at different stages of adulthood, given the very different rates of adoption and transition between 225 product use categories between younger and older adults. One limitation of this study is that we did not 226 incorporate data from the Adult Telephone Survey conducted in 2020; we chose to omit these data for 227 this analysis because of the sample size and change in data collection methods. Additionally, our work is 228 limited by our focus only on adults and by a reduced set of age categories compared to previous work.⁷ 229 These changes were made so that the subgroups that had sufficient sizes to support inferences about all 230 the transitions of interest. We plan to analyze youth transitions in separate work with models using a set 231 of product use categories and transitions tailored to the youth population. Finally, our work does not 232 account for the use of other tobacco products, such as cigars, cigarillos, or oral nicotine pouches.

233 As we discussed above, although many of the changes identified in this analysis appear to be positive 234 from the point of view of reducing cigarette use, the overall public health implications are likely minimal. 235 The US Food and Drug Administration (FDA) is currently determining which ENDS should be authorized 236 and potentially marketed as reduced risk products. Their primary regulatory challenge is to make 237 decisions that encourage cigarette cessation or reduced cigarette use among adults who use cigarettes, while limiting ENDS use among youth and young adults who would never have initiated tobacco use in 238 239 the absence of ENDS.¹⁸ While some tobacco-flavored ENDS have received FDA marketing authorization, 240 it is not clear if or when other flavored ENDS could be authorized. In the meantime, a regulation banning 241 non-tobacco characterizing flavors, including menthol, in cigarettes and cigars has been proposed.⁵⁰ It 242 will be important to continue to monitor how transitions in product use continue to change in response 243 to regulatory changes, changes in the marketplace, and future public health events.

244

245 What this paper adds

It is uncertain how recent changes in the marketplace, as well as events including the lung injury
 outbreak, COVID-19 pandemic, and ENDS flavor restrictions have impacted real-world product
 transition patterns.

- Underlying transition hazard rates can explain changes in observed transition probabilities
 between different patterns of cigarettes and ENDS use.
- We estimated how transition rates and probabilities changed from 2017–19 to 2019–21.
- We found decreased cigarette initiation, increased cessation from ENDS-only use, and increased transitions from dual to ENDS-only use among adults overall. ENDS uptake among cigarette-only users was highest among young adults.
- Dual use remained uncommon (1.9% among adults overall) and ENDS uptake among adult
 cigarette users remained low (<5% overall), so the population public health impact of the
 increase in the dual to ENDS-only use transition is likely to be limited.
- 258
- 259
- 260

261 Acknowledgments

262 This project was funded through National Cancer Institute (NCI) and Food and Drug Administration (FDA)

- 263 grant U54CA229974. The opinions expressed in this article are the authors' own and do not reflect the
- views of the National Institutes of Health, the Department of Health and Human Services, or the United
- 265 States government.

266

267 **Competing interests**

268 All authors declare that they have no competing interests.

269

270 **Contributors**

271 Conceptualisation and methodology: AFB and RMe; data curation: JJ and EJ-M; analysis and original

draft preparation: AFB; review and editing: AFB, JJ, EJ-M, SRL, TRH, ASF, JT, RMi, DTL and RMe; funding

273 acquisition: RMe and DTL; guarantor: AFB.

274

275 Data availability statement

276 Most data are available in a public, open access repository. Other data may be obtained from a third 277 party and are not publicly available. Public Use Files from the Population Assessment of Tobacco and 278 Health Study are available for download from open access repository an (https://doi.org/10.3886/ICPSR36498.v18). 279 **Restricted-use** files 280 (https://doi.org/10.3886/ICPSR36231.v37) require a restricted data use agreement. Conditions of use

are available on the aforementioned websites.

283 **References**


- 2841.Huang J, Duan Z, Kwok J, et al. Vaping versus JUULing: How the extraordinary growth and285marketing of JUUL transformed the US retail e-cigarette market. *Tob Control.* 2019;28(2):146-286151. doi:10.1136/tobaccocontrol-2018-054382
- Ali FRM, Diaz MC, Vallone D, et al. E-cigarette Unit Sales, by Product and Flavor Type United
 States, 2014–2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(37):1313-1318.
 doi:10.15585/mmwr.mm6937e2
- Hammond D, Reid JL, Burkhalter R, et al. Trends in e-cigarette brands, devices and the nicotine
 profile of products used by youth in England, Canada and the USA: 2017-2019. *Tob Control.*2021:1-11. doi:10.1136/tobaccocontrol-2020-056371
- Leventhal AM, Madden DR, Peraza N, et al. Effect of Exposure to e-Cigarettes With Salt vs Free Base Nicotine on the Appeal and Sensory Experience of Vaping: A Randomized Clinical Trial.
 JAMA Netw open. 2021;4(1):e2032757. doi:10.1001/jamanetworkopen.2020.32757
- 2965.US Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon297General.; 2020.
- 2986.Brouwer AF, Jeon J, Hirschtick JL, et al. Transitions between cigarette, ENDS and dual use in299adults in the PATH study (waves 1–4): multistate transition modelling accounting for complex300survey design. Tob Control. 2022;31(3):424-431. doi:10.1136/tobaccocontrol-2020-055967
- 3017.Brouwer AF, Jeon J, Jimenez-Mendoza E, et al. Changing patterns of cigarette and ENDS302transitions in the USA: a multistate transition analysis of youth and adults in the PATH Study in3032015–2017 vs 2017–2019. Tob Control. March 2023:tc-2022-057905. doi:10.1136/tc-2022-304057905
- 3058.Krishnasamy VP, Hallowell BD, Ko JY, et al. Update: Characteristics of a Nationwide Outbreak of306E-cigarette, or Vaping, Product Use-Associated Lung Injury United States, August 2019-January3072020. Morb Mortal Wkly Rep. 2020;69(3):90-94. doi:10.15585/mmwr.mm6903e2
- 3089.Cadham CJ, Sanchez-Romero LM, Fleischer NL, et al. The actual and anticipated effects of a309menthol cigarette ban: A scoping review. BMC Public Health. 2020;20(1):1-17.310doi:10.1186/s12889-020-09055-z
- 31110.Levy DT, Yuan Z, Li Y, Alberg AJ, Cummings KM. A modeling approach to gauging the effects of312nicotine vaping product use on cessation from cigarettes: what do we know, what do we need to313know? Addiction. 2019;114(S1):86-96. doi:10.1111/add.14530
- 31411.Levy DT, Cummings KM, Villanti AC, et al. A framework for evaluating the public health impact of315e-cigarettes and other vaporized nicotine products. Addiction. 2017;112(1):8-17.316doi:10.1111/add.13394
- Levy DT, Borland R, Villanti AC, et al. The Application of a Decision-Theoretic Model to Estimate
 the Public Health Impact of Vaporized Nicotine Product Initiation in the United States. *Nicotine Tob Res.* 2017;19(2):149-159. doi:10.1093/ntr/ntw158
- 32013.Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised321controlled trial. Lancet. 2013;382(9905):1629-1637. doi:10.1016/S0140-6736(13)61842-5
- 32214.Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of E-cigarettes versus nicotine-323replacement therapy. N Engl J Med. 2019;380(7):629-637. doi:10.1056/NEJMoa1808779

- McNeill A. Should clinicians recommend e-cigarettes to their patients who smoke? Yes. Ann Fam
 Med. 2016;14(4):300-301. doi:10.1370/afm.1962
- Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation.
 Cochrane Database Syst Rev. 2020;100(5):867. doi:10.1002/14651858.CD010216.pub4
- 32817.McKelvey K, Baiocchi M, Ramamurthi D, McLaughlin S, Halpern-Felsher B. Youth say ads for329flavored e-liquids are for them. Addict Behav. 2019;91:164-170.330doi:10.1016/j.addbeh.2018.08.029
- 33118.Kasza KA, Hammond D, Reid JL, Rivard C, Hyland A. Youth Use of e-Cigarette Flavor and Device332Combinations and Brands Before vs After FDA Enforcement. JAMA Netw open.3332023;6(8):e2328805. doi:10.1001/jamanetworkopen.2023.28805
- Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: A
 systematic review and meta-analysis. *Lancet Respir Med*. 2016;4(2):116-128. doi:10.1016/S2213 2600(15)00521-4
- 33720.Bhatnagar A, Payne TJ, Robertson RM. Is There A Role for Electronic Cigarettes in Tobacco338Cessation? J Am Heart Assoc. 2019;8(12):10-13. doi:10.1161/JAHA.119.012742
- Wang RJ, Bhadriraju S, Glantz SA. E-Cigarette Use and Adult Cigarette Smoking Cessation: A
 Meta-Analysis. *Am J Public Health*. 2021;111(2):230-246. doi:10.2105/AJPH.2020.305999
- 22. Cobb CO, Villanti AC, Graham AL, et al. Markov Modeling to Estimate the Population Impact of
 Emerging Tobacco Products: A Proof-of-Concept Study. *Tob Regul Sci.* 2015;1(2):129-141.
 doi:10.18001/TRS.1.2.3
- Hair EC, Romberg AR, Niaura R, et al. Longitudinal Tobacco Use Transitions Among Adolescents
 and Young Adults: 2014–2016. *Nicotine Tob Res*. 2019;21(4):458-468. doi:10.1093/ntr/ntx285
- Niaura R, Rich I, Johnson AL, et al. Young Adult Tobacco and E-cigarette Use Transitions:
 Examining Stability Using Multistate Modeling. *Nicotine Tob Res.* 2020;22(5):647-654.
 doi:10.1093/ntr/ntz030
- 34925.Loukas A, Marti CN, Harrell MB. Electronic Nicotine Delivery Systems Use Predicts Transitions in350Cigarette Smoking among Young Adults. Drug Alcohol Depend. 2021;231(December3512021):109251. doi:10.1016/j.drugalcdep.2021.109251
- 35226.Mantey DS, Harrell MB, Chen B, Kelder SH, Perry CL, Loukas A. A Longitudinal Examination of353Behavioral Transitions among Young Adult Menthol and Non-Menthol Cigarette Smokers Using a354Three-State Markov Model. Nicotine Tob Res. 2021;23(6):1047-1054. doi:10.1093/ntr/ntaa240
- Brouwer AF, Jeon J, Cook SF, et al. The Impact of Menthol Cigarette Flavor in the U.S.: Cigarette
 and ENDS Transitions by Sociodemographic Group. *Am J Prev Med.* 2022;62(2):243-251.
 doi:10.1016/j.amepre.2021.08.007
- Brouwer AF, Levy DT, Jeon J, et al. The Impact of Current Tobacco Product Use Definitions on
 Estimates of Transitions Between Cigarette and ENDS Use. *Nicotine Tob Res*. 2022;24(11):1756 1762. doi:10.1093/ntr/ntac132
- 361 29. Shafie-Khorassani F, Piper ME, Jorenby DE, et al. Associations of Demographics, Dependence, and 362 Biomarkers With Transitions in Tobacco Product Use in a Cohort of Cigarette Users and Dual 363 Users of Cigarettes and E-cigarettes. Nicotine Tob Res. 2022;(August):1-8. 364 doi:10.1093/ntr/ntac207

- 365 30. Schwamm E, Noubary F, Rigotti NA, Reddy KP. Longitudinal transitions in initiation, cessation, and 366 relapse of cigarette smoking and e-cigarette use among US youth and adults: Validation of a 367 microsimulation model. PLoS Cowlev Η. ed. One. 2023;18(4):e0284426. doi:10.1371/journal.pone.0284426 368
- 369 31. Parnham JC, Vrinten C, Radó MK, Bottle A, Filippidis FT, Laverty AA. Multistate transition
 370 modelling of e-cigarette use and cigarette smoking among youth in the UK. *Tob Control*. March
 371 2023:tc-2022-057777. doi:10.1136/tc-2022-057777
- 37232.JacksonC.Multi-statemodellingwithR:themsmpackage.2019:1-57.373http://www.jstatsoft.org/v38/i08/.
- 374 33. US Department of Health and Human Services. Surgeon General releases advisory on e-cigarette
 approximation and services and services and services. Surgeon general.gov/documents/surgeon-generals advisory-on-e-cigarette-use-among-youth-2018.pdf. Published 2018. Accessed August 4, 2023.
- 34. Hall W, Gartner C, Bonevski B. Lessons from the public health responses to the US outbreak of
 vaping-related lung injury. *Addiction*. 2021;116(5):985-993. doi:10.1111/add.15108
- 379 35. Moustafa AF, Rodriguez D, Mazur A, Audrain-McGovern J. Adolescent perceptions of E-cigarette
 380 use and vaping behavior before and after the EVALI outbreak. *Prev Med (Baltim)*.
 381 2021;145:106419. doi:10.1016/j.ypmed.2021.106419
- 38236.Morgan JC, Silver N, Cappella JN. How did beliefs and perceptions about e-cigarettes change after383national news coverage of the EVALI outbreak? *PLoS One*. 2021;16(4):e0250908.384doi:10.1371/journal.pone.0250908
- 385 37. Kreslake JM, Diaz MC, Shinaba M, Vallone DM, Hair EC. Youth and young adult risk perceptions
 386 and behaviours in response to an outbreak of e-cigarette/vaping-associated lung injury (EVALI) in
 387 the USA. *Tob Control*. 2022;31(1):88-97. doi:10.1136/tobaccocontrol-2020-056090
- 388 38. East K, Reid JL, Burkhalter R, et al. Exposure to Negative News Stories About Vaping, and Harm
 389 Perceptions of Vaping, Among Youth in England, Canada, and the United States Before and After
 390 the Outbreak of E-cigarette or Vaping-Associated Lung Injury ('EVALI'). Nicotine Tob Res.
 391 2022;24(9):1386-1395. doi:10.1093/ntr/ntac088
- 39239.Hall W, Gartner C, Bonevski B. Lessons from the public health responses to the US outbreak of393vaping-related lung injury. Addiction. 2021;116(5):985-993. doi:10.1111/add.15108
- 394 40. Svenson MRE, Freeman TP, Maynard OM. The Effect of Conflicting Public Health Guidance on
 395 Smokers' and Vapers' E-cigarette Harm Perceptions. *Nicotine Tob Res*. 2022;24(12):1945-1950.
 396 doi:10.1093/ntr/ntac163
- 41. East K, Reid JL, Burkhalter R, et al. Exposure to Negative News Stories About Vaping, and Harm
 Perceptions of Vaping, Among Youth in England, Canada, and the United States Before and After
 the Outbreak of E-cigarette or Vaping-Associated Lung Injury ('EVALI'). Nicotine Tob Res.
 2022;24(9):1386-1395. doi:10.1093/ntr/ntac088
- 401 42. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis.
 402 *Nicotine Tob Res.* 2020;22(9):1653-1656. doi:10.1093/ntr/ntaa082
- 43. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on
 404 COVID-19 severity: A systematic review and meta-analysis. *J Med Virol.* 2021;93(2):1045-1056.
 405 doi:10.1002/jmv.26389
- 406 44. Shastri MD, Shukla SD, Chong WC, et al. Smoking and COVID-19: What we know so far. *Respir*


- 407 *Med*. 2021;176:106237. doi:10.1016/j.rmed.2020.106237
- 408 45. Elling JM, Crutzen R, Talhout R, de Vries H. Tobacco smoking and smoking cessation in times of 409 COVID-19. *Tob Prev Cessat*. 2020;6:39. doi:10.18332/tpc/122753
- 46. Nyman AL, Spears CA, Churchill V, et al. Associations between COVID-19 risk perceptions and
 smoking and quitting behavior among U.S. adults. *Addict Behav Reports*. 2021;14:100394.
 doi:10.1016/j.abrep.2021.100394
- 413 47. Kalkhoran SM, Levy DE, Rigotti NA. Smoking and E-Cigarette Use Among U.S. Adults During the 414 COVID-19 Pandemic. *Am J Prev Med*. 2022;62(3):341-349. doi:10.1016/j.amepre.2021.08.018
- 41548.Kalkhoran SM, Levy DE, Rigotti NA. Smoking and E-Cigarette Use Among U.S. Adults During the416COVID-19 Pandemic. Am J Prev Med. 2022;62(3):341-349. doi:10.1016/j.amepre.2021.08.018
- 417 49. Klemperer EM, West JC, Peasley-Miklus C, Villanti AC. Change in Tobacco and Electronic Cigarette
 418 Use and Motivation to Quit in Response to COVID-19. *Nicotine Tob Res*. 2020;22(9):1662-1663.
 419 doi:10.1093/ntr/ntaa072
- 42050.US Food and Drug Administration. FDA Proposes Rules Prohibiting Menthol Cigarettes and421Flavored Cigars to Prevent Youth Initiation, Significantly Reduce Tobacco-Related Disease and422Death. https://www.fda.gov/news-events/press-announcements/fda-proposes-rules-prohibiting-423menthol-cigarettes-and-flavored-cigars-prevent-youth-initiation. Published April 28, 2022.424Accessed September 27, 2023.

Period • 2017–19 • 2019–21




Α.	Adults in 2017–20 Ages 18–90, N=28	•	ves	4–5)		B	B. Adults in 2019–2021 (Waves 5–6) Ages 18–90, N=24,751							
То							То							
Never established use only use use Non-current use Dual use						,e ,e	Never established use 98.6 0.8 0.2 0.3 0.0							
1	Never established use 98.	8 0.6	0.3	0.3	0.0		Never established use 98.	8.0	0.2	0.3	0.0			
	Non-current use	96.3	2.6	1.0	0.1		Non-current use	96.8	2.2	0.9	0.1			
From	Cigarette-only use	6.8	88.2	1.1	3.8	From	Cigarette-only use	7.1	88.2	0.7	4.0			
	ENDS-only use	13.9	1.4	78.2	6.5		ENDS-only use	18.1	1.3	75.7	4.9			
	Dual use	1.8	24.9	9.5	63.8		Dual use	3.6	26.3	20.1	50.0			

A. Ages 18–24 in 2017–2019 (Waves 4–5) N=8,891




B. Ages 18–24 in 2019–2021 (Waves 5–6) N=8,186



C. Ages 25–34 in 2017–2019 (Waves 4–5) N=5,794

E. Ages 25–34 in 2019–2021 (Waves 5–6) N=5,283



F. Ages 35–90 in 2017–2019 (Waves 4–5) N=13,373							G. Ages 35–90 in 2019–2021 (Waves 5–6) N=11,282							
То							То							
Never established use only use use Dual use Dual use						15 ⁰ 15 ⁰	Never established use 99.2 0.7 0.1 0.0 0.0							
٢	Never established use 99.3	0.5	0.2	0.0	0.0		Ne	ever established use 99.2	0.7	0.1	0.0	0.0		
	Non-current use	97.9	1.6	0.4	0.0			Non-current use	97.9	1.7	0.3	0.0		
From	Cigarette-only use	6.3	90.6	0.6	2.5		FOM	Cigarette-only use	6.3	91.1	0.3	2.3		
	ENDS-only use	11.3	1.1	82.7	4.9	-	-	ENDS-only use	12.9	1.1	82.1	3.8		
	Dual use	1.3	29.1	3.9	65.7			Dual use	2.6	32.3	16.8	48.2		